Acura Pharmaceuticals, Inc. announced the receipt of a $5.0 million milestone payment from King Pharmaceuticals, Inc. for successfully achieving the primary end points in Acura's pivotal phase III study, AP-ADF-105. Compared to placebo, Acurox (oxycodone HCl and niacin) tablets 5/30mg and 7.5/30mg both met the primary pain relief endpoint with p=.0001 and p<.0001, respectively.

Acurox tablets contain a unique composition of the opioid oxycodone HCl, niacin, and several functional inactive ingredients and are intended to relieve pain while deterring common methods of prescription drug abuse.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion (abuse deterrent) Technology and related product candidates.